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S U M M A R Y
Background: New cases of hepatitis B virus (HBV) infection continue to occur worldwide. Most of these
are due to mother-to-child transmission (MTCT), with maternal viraemia as the most important
contributing factor. The hepatitis B surface antigen (HBsAg) level, which correlates positively with viral
load, has been used for treatment monitoring in chronic hepatitis B. This study evaluated the usefulness
of quantitative HBsAg for viral load prediction in HBsAg-positive pregnant women.
Methods: A total of 943 pregnant women in Makassar, Indonesia, were screened for HBsAg. Sixty-four
women were HBsAg-positive and investigated. HBsAg level and hepatitis B e antigen (HBeAg)/hepatitis B
e antibody (anti-HBe) status were determined serologically. Viral load was measured by real-time PCR.
HBV DNA was sequenced and analysed for identiﬁcation of genotype and basal core promoter (BCP)/
precore (PC) mutations.
Results: Of 64 subjects, 12 (18.8%) were HBeAg-positive and 52 (81.3%) were HBeAg-negative. HBsAg
and HBV DNA levels were signiﬁcantly higher in the HBeAg-positive group (p < 0.001). HBsAg and HBV
DNA levels were positively correlated in the HBeAg-positive group (r = 0.659; p = 0.02), but not in the
HBeAg-negative group (r = 0.194; p = 0.168). Low HBsAg levels (<3.0 log10 IU/ml) corresponded with
HBV DNA levels < 6.0 log10 IU/ml (r = 0.404; p = 0.001), a recognized threshold for MTCT. Genotype C
was more prevalent than genotype B, but not associated with HBsAg level, viral load, or HBeAg status.
Two-thirds of HBeAg-negative subjects with high HBV DNA levels harboured BCP (A1762T/G1764A) and/
or PC (G1896A) variants.
Conclusions: HBsAg levels provide a good viral load predictor in HBeAg-positive but not HBeAg-negative
pregnant women. The HBeAg-negative group had a frequent occurrence of BCP/PC variants, which may
have contributed to the lack of correlation observed. Samples with a low HBsAg level, which is associated
with a low risk of MTCT, do not require HBV DNA measurement.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Paciﬁc, and Sub-Saharan Africa, most HBV infection occurs
perinatally or during early childhood. This is associated with a
high rate of persistent infection and increased risk of morbidity
and mortality from cirrhosis and hepatocellular carcinoma later
in life.1
Efforts in the prevention of hepatitis B have focused on the
immunization of infants implemented in 183 World Health
Organization (WHO) member states. As of 2012, 94 member
states including Indonesia had introduced the hepatitis B birthciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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disease burden, carrier rate, and HBV-related morbidity and
mortality.2 However, 50 million new cases of HBV infection
continue to be diagnosed annually, with the highest incidence due
to mother-to-child transmission (MTCT). Despite the administra-
tion of hepatitis B immunization (active) or active plus hepatitis B
immune globulin (HBIG) at birth, at least 10% of infants born to
HBV-carrying mothers still suffer HBV infection.3 Several factors
such as maternal serum HBV DNA level, hepatitis B e antigen
(HBeAg) status, HBV S gene variation, mode of delivery, and
neonatal immune deﬁciency have been related to MTCT. Of these
factors, maternal HBV DNA level has been identiﬁed as the most
relevant.4 Practice guidelines from major professional associations
address the decision for antiviral treatment in pregnant women
based on the HBV DNA threshold.4–6
Assays for HBV DNA quantiﬁcation with high sensitivity and
speciﬁcity are currently available. However, the routine application
of these methods for screening pregnant women is hampered by cost
and limited resources. In recent years, the hepatitis B surface antigen
(HBsAg) level, which correlates positively with viral load, has been
used as a biomarker to predict disease status and to monitor the
treatment response in chronic hepatitis B (CHB).7,8 The HBsAg level
correlates with covalently closed circular DNA (cccDNA) in
hepatocytes and can be considered a surrogate marker of infected
cells.9 One attraction of the use of the HBsAg level is that the assay is
less costly, is suitable for high-throughput screening, and its
platforms are commonly used in many laboratories. However, some
studies have reported that HBsAg quantiﬁcation correlates poorly
with the HBV DNA level. HBsAg and HBV DNA levels may vary during
different phases of CHB and the correlation is associated with the
HBeAg status of the patient.10–12 Certain HBV variants with basal
core promoter (BCP) A1762T/G1764A or precore (PC) G1896A
mutations could inﬂuence the synthesis of HBeAg.13 The presence of
these variants needs to be taken into account since they often occur
in endemic areas and may be associated with certain HBV genotypes
that differ among geographical regions.14,15
This study aimed to evaluate the usefulness of quantitative
HBsAg as a viral load predictor in pregnant women with CHB in
Makassar, Indonesia, and to analyse the association of the HBsAg
level and viral load with the HBeAg status, as well as the molecular
characteristics of HBV variants defective for HBeAg production.
2. Materials and methods
2.1. Study population
This cross-sectional study was carried out from January to July
2014 in the antenatal care units of Wahidin Sudirohusodo Hospital,
Hasanuddin University Hospital, Fatimah Mother and Child
Hospital, Pertiwi Mother and Child Hospital, Labuang Baji Hospital,
and Ibnu Sina Hospital, as well as several maternity clinics, in
Makassar, South Sulawesi. A total of 943 pregnant women were
screened for HBV infection; 64 of them were HBsAg-positive and
considered eligible for enrolment. For inclusion it was required
that the woman had been HBsAg-positive for >6 months without
prior antiviral therapy.16 Subjects co-infected with hepatitis A
virus, hepatitis C virus, or human immunodeﬁciency viruses, as
well as those with evidence of liver diseases, were excluded. This
study was approved by the Ethics Committee of the Faculty of
Medicine, Hasanuddin University, Makassar, Indonesia. Written
informed consent was obtained from each patient.
2.2. Serological examination
HBsAg status was determined by VIDAS HBsAg immunoassay
(bioMe´rieux SA, Marcy l’Etoile, France). HBeAg and hepatitis B eantibody (anti-HBe) were tested using Monolisa HBeAg-Ab PLUS
immunoassay (Bio-Rad, Marnes-la-Coquette, France). HBsAg
quantiﬁcation was done using Elecsys HBsAg Quant II (Roche
Diagnostics, Indianapolis, USA) on a Roche Cobas e411 Immunoa-
nalyzer following the manufacturer’s protocol.
2.3. HBV DNA detection and analysis
The HBV DNA level was determined from 500 ml of serum by
quantitative real-time PCR (CobasTaqman HBV Test; Roche
Diagnostics, Indianapolis, USA) with a range of linearity between
6 and 1.1  108 IU/ml. HBV DNA for molecular analysis was
obtained by extracting the DNA from 140 ml of serum using the
QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) and ampliﬁca-
tion by nested PCR using primers S2-1/S1-2 for the ﬁrst-round and
S88/S2-2 for the second-round (Supplementary Material,
Table S1).12 Amplicons were puriﬁed using a PCR puriﬁcation
column (Qiagen, Valencia, CA, USA) and subjected to direct
sequencing on a DNA sequence analyzer ABI 3130xl (Applied
Biosystems, Carlsbad, CA, USA).
The HBV genotype was determined by phylogenetic analysis
based on the 226-nucleotide sequences of the S gene compared
with 70 reference sequences of known genotypes (A–H) retrieved
from GenBank, using Phylip 3.68 software with the Kimura 2-
parameter model, neighbour-joining algorithm, and 1000 boot-
strapping.12
2.4. Identiﬁcation of BCP and PC mutations
Ampliﬁcation of BCP and PC regions was done by nested PCR
using primers PC1/PC2 for the ﬁrst-round and S012/S013 for the
second-round (Supplementary Material, Table S1). Amplicons
were puriﬁed and sequenced as described previously.12 The
sequences were aligned with reference sequence M54923
retrieved from GenBank.
2.5. Statistical analysis
The baseline data were summarized descriptively. Continuous
and categorical variables were compared between groups using
the Mann–Whitney test and Chi-square/Fisher’s exact test,
respectively. Pearson’s correlation coefﬁcient was used to describe
the correlation between two continuous, normally distributed
variables. Spearman’s correlation was used for categorical vari-
ables or continuous variables that were not normally distribut-
ed.10,12,13 Statistical analyses were performed using IBM-SPSS v.
20 software (IBM Corp., Armonk, NY, USA). All statistical
signiﬁcance values were assessed at p < 0.05.
3. Results
3.1. Characteristics of study subjects
Among 943 pregnant women attending several antenatal
clinics in Makassar, 64 (6.8%) were HBsAg-positive. Of these
women, 12 (18.8%) were HBeAg-positive and 52 (81.3%) were
HBeAg-negative. HBV DNA levels were signiﬁcantly higher in the
HBeAg-positive group (median 7.43 log10 IU/ml) than in the
HBeAg-negative group (median 1.55 log10 IU/ml) (p < 0.001).
Similarly, HBsAg levels were signiﬁcantly higher in the HBeAg-
positive group (median 4.21 log10 IU/ml) than in the HBeAg-
negative group (median 2.91 log10 IU/ml) (p < 0.001). Age, alanine
aminotransferase (ALT) levels, and HBV genotype distribution
were comparable in the two groups (Table 1 and Supplementary
Material Table S2).
Table 1
Baseline characteristics of HBsAg-positive pregnant womena
Parameter Overall
(n = 64)
HBeAg-positive
(n = 12)
HBeAg-negative
(n = 52)
p-Valueb
Age (years) 29 (18–42) 28.5 (22–42) 30 (18–41) 0.564
ALT (IU/l) 24.5 (9–129) 27 (16–129) 24.5 (9–88) 0.129
HBV DNA (log10 IU/ml) 1.71 (0.78–8.05) 7.43 (1.54–8.05) 1.54 (0.78–6.48) <0.001
HBsAg (log10 IU/ml) 3.03 (0.70–4.11) 4.21 (3.25–4.91) 2.91 (0.70–4.11) <0.001
Ratio HBsAg/HBV DNA (log10 IU/ml) 1.25 (0.40–5.30) 0.61 (0.56–0.7556) 1.43 (0.90–2.78) <0.001
Genotype (n = 47)
B 8 (17.0%) 2 (22.2%) 6 (15.8%) 0.889
C 39 (83.0%) 7 (77.8%) 32 (84.2%)
HBeAg, Hepatitis B e antigen; ALT, alanine aminotransferase; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen.
a Results are reported as the median (minimum–maximum), or number (percentage of detected samples).
b Comparison between HBeAg-positive and HBeAg-negative groups (Mann–Whitney U-test or Chi-square test).
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pregnant women according to HBeAg status
HBV DNA levels were categorized into <3.0 log10 IU/ml (close to
3.3 log10 IU/ml or 2000 IU/ml, which is the threshold to deﬁne
inactive carrier state of CHB),17 3.0–6.0 log10 IU/ml, and 6.0 log10
IU/ml (a level associated with HBV immunoprophylaxis failure).18
The proportions of pregnant women with HBV DNA levels <3.0
log10 IU/ml, 3.0–6.0 log10 IU/ml, and 6.0 log IU/ml in the HBeAg-
positive group were 9% (1/12), 25% (3/12), and 67% (8/12),
respectively; in the HBeAg-negative group, the proportions were
83% (43/52), 13% (7/52), and 4% (2/52), respectively (Figure 1A).
3.3. Distribution of serum HBsAg levels among the HBsAg-positive
pregnant women according to HBeAg status
HBsAg levels were categorized into <3.0 log10 IU/ml (a level
associated with a lower risk of CHB outcomes), 3.0–4.0 log10 IU/ml,
and 4.0 log10 IU/ml.5 The proportions of subjects with HBsAg
levels <3.0 log10 IU/ml, 3.0–4.0 log10 IU/ml, and 4.0 log10 IU/ml
were 0% (0/12), 42% (5/12), and 58% (7/12), respectively, in the
HBeAg-positive group, and 58% (30/52), 35% (18/52), and 8% (4/52),
respectively, in the HBeAg-negative group (Figure 1B).
3.4. Correlation between HBsAg and HBV DNA levels
In all 64 HBsAg-positive subjects, serum HBsAg and HBV DNA
levels showed a signiﬁcantly moderate correlation (r = 0.513; p <
0.001) (Figure 2A). When analysed separately according to HBeAg
status, there was a strong correlation between HBV DNA and
HBsAg levels in the HBeAg-positive group (r = 0.659; p = 0.02)
(Figure 2B), but no correlation was observed in the HBeAg-negative
group (r = 0.194; p = 0.168) (Figure 2C).19
There were four subjects (M150, M414, M415, and M818) with
high HBsAg levels (>4.0 log10 IU/ml) but low HBV DNA levels (<3.0
log10 IU/ml). In contrast, there were four subjects (M167, M173,
M258, and M810) with low HBsAg levels (<3.0 log10 IU/ml) but
who had moderate viraemia (3.0–6.0 log10 IU/ml). However, in
most cases, low levels of HBsAg were associated with low levels of
HBV DNA; HBsAg levels <3.0 log10 IU/ml were signiﬁcantly
correlated to HBV DNA levels <3.0 log10 IU/ml (r = 0.363; p = 0.003)
and to HBV DNA levels <6.0 log10 IU/ml (r = 0.404; p = 0.001). No
subjects with HBsAg levels <3.0 log10 IU/ml had HBV DNA 6.0
log10 IU/ml (Figure 3).
3.5. HBsAg and HBV DNA levels in genotype B and C
HBV genotype was successfully determined in 47 pregnant
women based on the S gene sequences (sequencing was not
possible in the other subjects because of insufﬁcient HBV DNAcontent). The sequences generated have been deposited in the
GenBank database (accession numbers KP241791–KP241837).
Median HBsAg and HBV DNA levels were not signiﬁcantly different
in each genotype. Genotype C was more prevalent than genotype B
(83% vs. 17%), but the proportions were comparable between the
HBeAg-positive and HBeAg-negative groups (Figure 4).
3.6. Subgroup analysis for BCP and PC mutations in HBeAg-negative
pregnant women
Sequencing of the BCP/PC region of the HBV genome was
performed successfully in 12 HBeAg-negative subjects (sequencing
was not possible in the other subjects because of low HBV DNA
content). The sequences generated have been deposited in
GenBank (accession numbers KP241838–KP241844 and
KP241846–KP241850). Four subjects had the wild-type HBV
DNA sequence at both the BCP and PC sites, four had the BCP
mutation alone, and two had the PC mutation alone. Concurrent
BCP and PC mutations were detected in two subjects. All subjects
with the BCP mutation had HBV genotype C, while the PC mutation
was detected in two subjects with genotype B and one subject with
genotype C (Table 2).
4. Discussion
This study represents one of few reports of HBV infection in
pregnant women from Indonesia. Of 943 pregnant women
attending several antenatal clinics in Makassar, 64 (6.8%) were
HBsAg-positive. This ﬁgure is higher than that reported recently
from Jakarta (2.2%),20 and other places in Indonesia reported
around 1985 (4.7% in West Java, 1.9% in Bali, 3.4% in Mataram).21,22
The wide variation in HBV infection rates may be associated with
the general HBsAg prevalence in Indonesia (3.4–19.5%), geograph-
ical variation, and differences in cultural practices, as well as the
methods used to detect HBV infection.23,24 This fact is of concern,
because it occurs in pregnant women who tend to be in the
immune-tolerant phase of CHB with normal physical/laboratory
examinations and high-level viraemia, but unaware of their
HBsAg-positive status.
Varying thresholds of maternal HBV DNA have been discussed
in association with MTCT and immunoprophylaxis failure. Wise-
man reported that immunoprophylaxis failure occurred in infants
when the maternal viral load was 8 log10 copies/ml (>1.7  107
IU/ml).25 Zou et al. showed that the immunoprophylaxis failure
increased with higher levels of maternal HBV DNA.18 When the
mothers’ HBV DNA levels were stratiﬁed to <6, 6–6.99, 7–7.99, and
8 log10 copies/ml, the corresponding rates of immunoprophylaxis
failure were 0%, 3.2%, 6.7%, and 7.6%, respectively, and it was
concluded that an antenatal HBV DNA level >6 log10 copies/ml
(>200 000 IU/ml) was the most important predictor of MTCT.18
Figure 1. Distribution of (A) HBV DNA and (B) HBsAg levels among pregnant women according to HBeAg status: (i) among the HBeAg-positive group (n = 12) and (ii) among
the HBeAg-negative group (n = 52).
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guidelines recommend treating pregnant women when HBV DNA
levels are >2  106 IU/ml in the third trimester for the prevention
of MTCT.5,6 In the present study, 15.6% (10/64) of all subjects had
HBV DNA levels >6.0 log10 IU/ml, distributed in 67% (8/12) of the
HBeAg-positive group and 4% (2/52) of the HBeAg-negative group.
The fact that the subjects had a skewed distribution toward the
higher levels of HBV DNA should be regarded as important, as this
shows a higher possibility of MTCT.
There are few studies on the potential applications of
quantitative HBsAg in the management of hepatitis B during
pregnancy.16,26 To the best of the authors’ knowledge, this is theFigure 2. Correlation of HBsAg and HBV DNA levels in pregnant women according to HB
HBsAg and HBV DNA levels in HBeAg-positive women (n = 12); (C) correlation of HBsAg an
levels are calculated in log10 IU/ml. The correlation is regarded very weak for r = 0–0.19, w
strong for r = 0.80–1.19.ﬁrst study to evaluate the relationship between HBsAg and HBV
DNA levels with regard to HBeAg status in pregnant women with
CHB in Indonesia. This study revealed that among all 64 HBsAg-
positive pregnant women, the HBsAg level was correlated with the
HBV DNA level regardless of age and viral genotype. When
stratiﬁed based on HBeAg status, the correlation was strong in
HBeAg-positive pregnant women but missing in the HBeAg-
negative women. A possible explanation for this ﬁnding is that
HBsAg synthesis has a pathway distinct from HBV DNA synthesis
and under the inﬂuence of different immune-control mecha-
nisms.27,28 HBsAg is present as a component of HBV virions but also
as subviral particles, which exceed the number of virions.9
Pregnant women with an HBeAg-positive status could be in theeAg status: (A) overall correlation in all pregnant women (n = 64); (B) correlation of
d HBV DNA levels in HBeAg-negative women (n = 52). Both the HBV DNA and HBsAg
eak for r = 0.20–0.39, moderate for r = 0.40–0.59, strong for r = 0.60–0.79, and very
Figure 3. Distribution of HBV DNA levels among pregnant women according to
HBsAg levels. In most cases, low levels of HBsAg were associated with low levels of
HBV DNA; HBsAg levels <3.0 log10 IU/ml were signiﬁcantly correlated to HBV DNA
levels <3.0 log10 IU/ml (r = 0.363; p = 0.003) and to HBV DNA levels <6.0 log10 IU/ml
(r = 0.404; p = 0.001). No subjects with HBsAg levels <3.0 log10 IU/ml had HBV DNA
6.0 log10 IU/ml.
Table 2
BCP/PC mutations, HBV DNA and HBsAg levels, and HBV genotype in 12 HBeAg-
negative pregnant women
Subject
code
BCP
mutation
A1762T/
G1764A
PC
mutation
G1896A
HBV DNA
(log10 IU/ml)
HBsAg
(log10 IU/ml)
Genotype
M177 + + 6.48 3.46 C
M384 +  6.08 3.04 C
M167  + 4.55 2.69 B
M810   3.50 2.70 C
M218 +  3.29 3.56 C
M336 + + 2.70 3.74 C
M150   2.62 4.00 C
M898  + 2.08 3.04 B
M253   1.36 3.05 C
M818 +  1.34 4.11 C
M19A   0.78 2.51 C
M212 +  0.78 3.55 C
BCP, basal core promoter; PC, precore; HBV, hepatitis B virus; HBsAg, hepatitis B
surface antigen; HBeAg, hepatitis B e antigen.
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minimally subjected to the host immune reaction, while those
with an HBeAg-negative status could be in the low-replicative
phase of CHB where the number of virions has decreased as a result
of successful immune control.12,27 Therefore, the reduction in
HBsAg levels was not proportional to that of HBV DNA levels. The
ratio of HBsAg/HBV DNA reﬂects the association between HBsAg
production and HBV replication; this was signiﬁcantly higher in
HBeAg-negative subjects than in the HBeAg-positive group
(median 1.43 vs. 0.61 log10 IU/ml, respectively).
Four pregnant women had high HBsAg levels with low HBV
DNA. As explained, this could be due to the larger excess of HBsAgFigure 4. Distribution of serum HBV DNA (A) and HBsAg (B) levels in subjects with HBV
comparable in the two genotypes. Median values (max, min; log10 IU/ml) with 95% coover the number of virions.8 This implies that a high level of HBsAg
cannot be used to predict the HBV DNA level. The serum HBsAg
level should thus be used together with, but not as a substitute for,
HBV DNA.29 Four other subjects had low HBsAg levels but
moderate viraemia (>4 log10 IU/ml). Possible explanations for
the decreased detection of HBsAg include (1) differences in
analytical sensitivity and speciﬁcity in HBsAg detection of viruses
of different genotypes; (2) mutations in the pre-S/S gene that cause
HBsAg detection failure; (3) treatment-associated mutations that
cause derangement of the P gene with subsequent alteration of the
overlapping S gene; or (4) the concomitant presence of hepatitis B
surface antibodies (anti-HBs) leading to the formation of immune
complexes poorly displaced by HBsAg-capture antibodies.7,30,31 In
the majority of subjects, however, low levels of HBsAg (<3.0 log10
IU/ml) correlated signiﬁcantly with low levels of HBV DNA (<6.0 genotype B (n = 8) and HBV genotype C (n = 39). HBV DNA and HBsAg levels were
nﬁdence intervals are shown.
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6,18 This result
suggests that HBV DNA quantiﬁcation may not be necessary for
pregnant mothers with low HBsAg levels.
Another important ﬁnding from this study was the presence of
HBeAg-negative pregnant women with high viraemia. These
women, with no evidence of liver disease, were apparently in the
inactive carriers of CHB. However, some inactive carriers may
have high HBV DNA levels accompanied by persistently normal
ALT levels.5 Studies have documented that certain HBV variants
with nucleotide substitutions in the PC and/or BCP regions could
abolish or down-regulate HBeAg production. These variants may
replicate rapidly in HBeAg-negative CHB, where HBsAg and HBV
DNA levels are preserved.13 Analysis for the presence of BCP
(A1762T/G1764A) and PC (G1896A) mutations was performed on
HBeAg-negative subjects who had HBV DNA levels >2000 IU/ml. A
substantial portion of isolates analysed, particularly from subjects
with HBV DNA levels >6.0 log10 IU/ml, had BCP and PC mutations
either alone or in combination. This ﬁnding is important because
the emergence of these variants frequently occurs in regions with
HBV endemicity.14,15 Notably, all BCP mutants identiﬁed had
genotype C, which was prevalent among the subjects studied. It
has been recognized that HBV genotype C and BCP mutations
are independent risk factors for progression to severe liver
disease.5,32
Important limitations of the present study include the relatively
small number of pregnant women with chronic HBV infection.
Wider clinical and community-based studies in different areas of
the Indonesian archipelago will be necessary to estimate the true
national burden of HBV infection in pregnant women. Also, the
cross-sectional design of the study could not represent the
ﬂuctuating proﬁle of CHB. Serial measurements of ALT levels are
necessary to distinguish the true inactive carriers from active
HBeAg-negative individuals. However, most studies have reported
that ALT levels are lower during pregnancy and viral load is more
likely to increase due to the natural immune suppression processes
linked to pregnancy.33
In conclusion, this study conﬁrms that serum HBsAg level may
be used as a predictor of the serum HBV DNA level in HBeAg-
positive pregnant women, but not in HBeAg-negative pregnant
women. The measurement of HBV DNA is not necessary if the level
of HBsAg is low, since the probability of detecting a high viral load
is low. An important role of BCP/PC variants inﬂuencing HBeAg
status independent of viral load was also identiﬁed, providing a
cautionary note to the interpretation of negative results of HBeAg
testing when classifying HBV-infected individuals. These results
offer the promise of practical guidance in using quantitative HBsAg
as a tool to better manage HBV-infected pregnant women. Follow-
up studies are needed to assess the impacts of the maternal and
virological factors discussed in this study on HBV carriage and
immunoprophylaxis failure in the infants born to these HBsAg-
positive mothers.
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